GlassScriptPhysician profile
Onyechi Megafu
NPI 1043690712
$36,810.27
in general payments reported to CMS, 2019-2025
26 companies · $3,924 in 2025
The $3,924 reported for 2025 was more than what 89% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,260 · 2020: $714 · 2021: $873 · 2022: $8,740 · 2023: $5,673 · 2024: $14K · 2025: $3,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $11,833.36 |
| Food and Beverage | $11,390.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,675.58 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $12,091.49 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $3,384.04 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Saluda Medical Americas, INC. | $2,849.32 | 2024-2025 | Evoke |
| Nevro Corp. | $1,234.94 | 2019-2023 | Senza |
| Curonix LLC | $968.52 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stryker Corporation | $735.61 | 2024-2025 | Spinejack, Optablate, Omnicurve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $662.81 | 2020-2025 | Relistor |
| Spr Therapeutics, INC | $602.76 | 2022-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $281.92 | 2020-2022 | |
| Medtronic USA, INC. | $155.81 | 2019-2020 | |
| Vertos Medical, INC. | $138.77 | 2024 | Mild Device Kit |
| Tersera Therapeutics LLC | $118.31 | 2022-2025 | Prialt |
| Lilly USA, LLC | $118.06 | 2022 | |
| Si-Bone, INC. | $114.34 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $109.52 | 2020-2022 | |
| Pfizer INC. | $107.31 | 2020-2021 | |
| Stimwave Technologies Incorporated | $92.50 | 2020 | |
| Heron Therapeutics, INC. | $80.52 | 2022 | |
| Averitas Pharma INC. | $79.98 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $69.16 | 2025 | |
| Scilex Pharmaceuticals INC. | $45.33 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $40.01 | 2021 | |
| Stratus Medical, LLC | $26.54 | 2023 | Nimbus |
| Foundation Fusion Solutions, LLC | $14.21 | 2024 | |
| Mallinckrodt Hospital Products INC. | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyechi Megafu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.